EGFR tyrosine kinase inhibitors (TKIs) versus durvalumab (durva) following concurrent chemoradiation (CRT) in unresectable EGFR-mutant non-small-cell lung cancer (NSCLC)

被引：0
|
作者：
Nassar, Amin
Adib, Elio
Feng, Jamie
Aredo, Jacqueline V.
Parikh, Kaushal
Harris, Jeremy Phillip
Manana, Ana I. Velazquez
Ragavan, Meera Vimala
Lin, Jessica Jiyeong
Piotrowska, Zofia
Fitzgerald, Bailey Gleason
Grohe, Christian
Sankar, Kamya
Neal, Joel W.
Wakelee, Heather A.
Shepherd, Frances A.
Herbst, Roy S.
Naqash, Abdul Rafeh
Goldberg, Sarah B.
Kim, So Yeon
机构：
[1] Yale Canc Ctr, New Haven, CT USA
[2] Brigham & Womens Hosp, Boston, MA USA
[3] UHN, Princess Margaret Canc Ctr, Toronto, ON, Canada
[4] Stanford Canc Inst, Stanford, CA USA
[5] Mayo Clin, Rochester, MN USA
[6] Univ Calif Irvine, Orange, CA USA
[7] Univ Calif San Francisco, San Francisco, CA USA
[8] Massachusetts Gen Hosp, Canc Ctr, Boston, MA USA
[9] Massachusetts Gen Hosp, Boston, MA USA
[10] Icahn Sch Med Mt Sinai, New York, NY USA
[11] ELK Berlin, Dept Resp Dis, Berlin, Germany
[12] Cedars Sinai Med Ctr, Los Angeles, CA USA
[13] Stanford Univ, Med Ctr, Stanford, CA USA
[14] Stanford Hosp & Clin, Stanford, CA USA
[15] Univ Hlth Network, Princess Margaret, Toronto, ON, Canada
[16] Yale New Haven, Yale Sch Med, Smilow Canc Hosp, Yale Canc Ctr, New Haven, CT USA
[17] Univ Oklahoma Hlth Sci, Stephenson Canc Ctr, Oklahoma City, OK USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8567
引用
下载
收藏
页数：1
相关论文
共 50 条
  • [1] Comment on "Consolidation Osimertinib Versus Durvalumab following Concurrent Chemoradiation in Unresectable EGFR-Mutant NSCLC "
    Chen, Ching-Yi
    Wang, Guo-Sheng
    Wei, James Cheng-Chung
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (05) : e6 - e7
  • [2] Receptor Tyrosine Kinase Fusions as an Actionable Resistance Mechanism to EGFR TKIs in EGFR-Mutant Non-Small-Cell Lung Cancer
    Zhu, Viola W.
    Klempner, Samuel J.
    Ou, Sai-Hong Ignatius
    TRENDS IN CANCER, 2019, 5 (11): : 677 - 692
  • [3] Osimertinib Versus Durvalumab Versus Observation After Chemoradiation in Unresectable EGFR-Mutant NSCLC
    Zhao, Binghao
    Yao, Longping
    Ma, Wenbin
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (05)
  • [4] EGFR-Mutant Non-Small-Cell Lung Cancer at Surgical Stages: What Is the Place for Tyrosine Kinase Inhibitors?
    Cansouline, Xavier
    Lipan, Beatrice
    Sizaret, Damien
    Tallet, Anne
    Vandier, Christophe
    Carmier, Delphine
    Legras, Antoine
    CANCERS, 2022, 14 (09)
  • [5] Targeting BRAF Activation as Acquired Resistance Mechanism to EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Non-Small-Cell Lung Cancer
    Aboubakar Nana, Frank
    Ocak, Sebahat
    PHARMACEUTICS, 2021, 13 (09)
  • [6] Acquired Resistance to EGFR tyrosine kinase inhibitors (TKIs) in EGFR-Mutant lung cancer among Hispanics (CLICaP)
    Zorrilla, A. Cardona
    Arrieta, O.
    Rojas, L.
    Corrales, L.
    Vargas, C.
    Carranza, H.
    Cuello, M.
    Martin, C.
    Rosell, R.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S15 - S15
  • [7] The Presence of Concomitant Mutations Affects the Activity of EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC) Patients
    Rachiglio, Anna Maria
    Fenizia, Francesca
    Piccirillo, Maria Carmela
    Galetta, Domenico
    Crino, Lucio
    Vincenzi, Bruno
    Barletta, Emiddio
    Pinto, Carmine
    Ferrau, Francesco
    Lambiase, Matilde
    Montanino, Agnese
    Roma, Cristin
    Ludovini, Vienna
    Montagna, Elisabetta Sara
    De Luca, Antonella
    Rocco, Gaetano
    Botti, Gerardo
    Perrone, Francesco
    Morabito, Alessandro
    Normanno, Nicola
    CANCERS, 2019, 11 (03):
  • [8] Adjuvant EGFR tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer: still an investigational approach
    Jassem, Jacek
    TRANSLATIONAL LUNG CANCER RESEARCH, 2019, 8 : S387 - S390
  • [9] Clinical Predictors of Response to EGFR Tyrosine Kinase inhibitors in Patients with EGFR-Mutant Non-Small Cell Lung Cancer
    Fukihara, Jun
    Watanabe, Naohiro
    Taniguchi, Hiroyuki
    Kondoh, Yasuhiro
    Kimura, Tomoki
    Kataoka, Kensuke
    Matsuda, Toshiaki
    Yokoyama, Toshiki
    Hasegawa, Yoshinori
    ONCOLOGY, 2014, 86 (02) : 86 - 93
  • [10] EGFR-TYROSINE KINASE INHIBITOR (TKI) RECHALLENGE WITH BEVACIZUMAB IN EGFR-MUTANT NON-SMALL CELL LUNG CANCER (NSCLC)
    Otsuka, K.
    Hata, A.
    Kato, R.
    Takeshita, J.
    Okuda, C.
    Kaji, R.
    Masago, K.
    Fujita, S.
    Katakami, N.
    ANNALS OF ONCOLOGY, 2014, 25
12345